Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors Article Swipe
Angel Qin
,
Songzhu Zhao
,
Abdul Miah
,
Lai Wei
,
Sandipkumar Patel
,
Andrew Johns
,
Madison Grogan
,
Erin M. Bertino
,
Kai He
,
Peter G. Shields
,
Gregory P. Kalemkerian
,
Shirish M. Gadgeel
,
Nithya Ramnath
,
Bryan J. Schneider
,
Khaled A. Hassan
,
Nicholas J. Szerlip
,
Zoey Chopra
,
Sara N. Journey
,
Jessica Waninger
,
Daniel Spakowicz
,
David P. Carbone
,
Carolyn J. Presley
,
Gregory A. Otterson
,
Michael D. Green
,
Dwight H. Owen
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.6004/jnccn.2020.7668
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.6004/jnccn.2020.7668
Background: Bone metastases and skeletal-related events (SREs) are a frequent cause of morbidity in patients with metastatic non–small cell lung cancer (mNSCLC). Data are limited on bone metastases and SREs in patients with mNSCLC treated using immune checkpoint inhibitors (ICIs), and on the efficacy of bone-modifying agents (BMAs) in this setting. Here we report the incidence, impact on survival, risk factors for bone metastases and SREs, and impact of BMAs in patients with mNSCLC treated with ICIs in a multi-institutional cohort. Patients and Methods: We conducted a retrospective study of patients with mNSCLC treated with ICIs at 2 tertiary care centers from 2014 through 2017. Overall survival (OS) was compared between patients with and without baseline bone metastases using a log-rank test. A Cox regression model was used to evaluate the association between OS and the presence of bone metastases at ICI initiation, controlling for other confounding factors. Results: We identified a cohort of 330 patients who had received ICIs for metastatic disease. Median patient age was 63 years, most patients were treated in the second line or beyond (n=259; 78%), and nivolumab was the most common ICI (n=211; 64%). Median OS was 10 months (95% CI, 8.4–12.0). In our cohort, 124 patients (38%) had baseline bone metastases, and 43 (13%) developed SREs during or after ICI treatment. Patients with bone metastases had a higher hazard of death after controlling for performance status, histology, line of therapy, and disease burden (hazard ratio, 1.57; 95% CI, 1.19–2.08; P =.001). Use of BMAs was not associated with OS or a decreased risk of SREs. Conclusions: Presence of bone metastases at baseline was associated with a worse prognosis for patients with mNSCLC treated with ICI after controlling for multiple clinical characteristics. Use of BMAs was not associated with reduced SREs or a difference in survival.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.6004/jnccn.2020.7668
- OA Status
- green
- Cited By
- 48
- References
- 27
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3153196512
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3153196512Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.6004/jnccn.2020.7668Digital Object Identifier
- Title
-
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint InhibitorsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-08-01Full publication date if available
- Authors
-
Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas J. Szerlip, Zoey Chopra, Sara N. Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, Dwight H. OwenList of authors in order
- Landing page
-
https://doi.org/10.6004/jnccn.2020.7668Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.ncbi.nlm.nih.gov/pmc/articles/8752085Direct OA link when available
- Concepts
-
Medicine, Internal medicine, Oncology, Hazard ratio, Proportional hazards model, Retrospective cohort study, Cohort, Lung cancer, Nivolumab, Cancer, Surgery, Confidence interval, ImmunotherapyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
48Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 9, 2024: 14, 2023: 13, 2022: 10, 2021: 1Per-year citation counts (last 5 years)
- References (count)
-
27Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3153196512 |
|---|---|
| doi | https://doi.org/10.6004/jnccn.2020.7668 |
| ids.doi | https://doi.org/10.6004/jnccn.2020.7668 |
| ids.mag | 3153196512 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/33878726 |
| ids.openalex | https://openalex.org/W3153196512 |
| fwci | 3.98359676 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D002289 |
| mesh[0].is_major_topic | True |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D006801 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Humans |
| mesh[2].qualifier_ui | Q000494 |
| mesh[2].descriptor_ui | D000082082 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | pharmacology |
| mesh[2].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[3].qualifier_ui | Q000627 |
| mesh[3].descriptor_ui | D000082082 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | therapeutic use |
| mesh[3].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[4].qualifier_ui | Q000473 |
| mesh[4].descriptor_ui | D008175 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | pathology |
| mesh[4].descriptor_name | Lung Neoplasms |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D008875 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Middle Aged |
| mesh[6].qualifier_ui | Q000627 |
| mesh[6].descriptor_ui | D000077594 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | therapeutic use |
| mesh[6].descriptor_name | Nivolumab |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D012189 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Retrospective Studies |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D002289 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D006801 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Humans |
| mesh[10].qualifier_ui | Q000494 |
| mesh[10].descriptor_ui | D000082082 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | pharmacology |
| mesh[10].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[11].qualifier_ui | Q000627 |
| mesh[11].descriptor_ui | D000082082 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | therapeutic use |
| mesh[11].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[12].qualifier_ui | Q000473 |
| mesh[12].descriptor_ui | D008175 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | pathology |
| mesh[12].descriptor_name | Lung Neoplasms |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D008875 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Middle Aged |
| mesh[14].qualifier_ui | Q000627 |
| mesh[14].descriptor_ui | D000077594 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | therapeutic use |
| mesh[14].descriptor_name | Nivolumab |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D012189 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Retrospective Studies |
| type | article |
| title | Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors |
| biblio.issue | 8 |
| biblio.volume | 19 |
| biblio.last_page | 921 |
| biblio.first_page | 915 |
| topics[0].id | https://openalex.org/T12379 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998000264167786 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Cancer Diagnosis and Treatment |
| topics[1].id | https://openalex.org/T10158 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9976000189781189 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Cancer Immunotherapy and Biomarkers |
| topics[2].id | https://openalex.org/T11221 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9973999857902527 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Bone health and treatments |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9649984836578369 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C126322002 |
| concepts[1].level | 1 |
| concepts[1].score | 0.7137370109558105 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[1].display_name | Internal medicine |
| concepts[2].id | https://openalex.org/C143998085 |
| concepts[2].level | 1 |
| concepts[2].score | 0.5957031846046448 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[2].display_name | Oncology |
| concepts[3].id | https://openalex.org/C207103383 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5891622304916382 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q3930246 |
| concepts[3].display_name | Hazard ratio |
| concepts[4].id | https://openalex.org/C50382708 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5189533233642578 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q223218 |
| concepts[4].display_name | Proportional hazards model |
| concepts[5].id | https://openalex.org/C167135981 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5178266167640686 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2146302 |
| concepts[5].display_name | Retrospective cohort study |
| concepts[6].id | https://openalex.org/C72563966 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4839220643043518 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q1303415 |
| concepts[6].display_name | Cohort |
| concepts[7].id | https://openalex.org/C2776256026 |
| concepts[7].level | 2 |
| concepts[7].score | 0.46925947070121765 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q47912 |
| concepts[7].display_name | Lung cancer |
| concepts[8].id | https://openalex.org/C2780030458 |
| concepts[8].level | 4 |
| concepts[8].score | 0.4629533886909485 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q7041828 |
| concepts[8].display_name | Nivolumab |
| concepts[9].id | https://openalex.org/C121608353 |
| concepts[9].level | 2 |
| concepts[9].score | 0.3675593137741089 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[9].display_name | Cancer |
| concepts[10].id | https://openalex.org/C141071460 |
| concepts[10].level | 1 |
| concepts[10].score | 0.33880293369293213 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[10].display_name | Surgery |
| concepts[11].id | https://openalex.org/C44249647 |
| concepts[11].level | 2 |
| concepts[11].score | 0.1734839379787445 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[11].display_name | Confidence interval |
| concepts[12].id | https://openalex.org/C2777701055 |
| concepts[12].level | 3 |
| concepts[12].score | 0.1676752269268036 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[12].display_name | Immunotherapy |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9649984836578369 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/internal-medicine |
| keywords[1].score | 0.7137370109558105 |
| keywords[1].display_name | Internal medicine |
| keywords[2].id | https://openalex.org/keywords/oncology |
| keywords[2].score | 0.5957031846046448 |
| keywords[2].display_name | Oncology |
| keywords[3].id | https://openalex.org/keywords/hazard-ratio |
| keywords[3].score | 0.5891622304916382 |
| keywords[3].display_name | Hazard ratio |
| keywords[4].id | https://openalex.org/keywords/proportional-hazards-model |
| keywords[4].score | 0.5189533233642578 |
| keywords[4].display_name | Proportional hazards model |
| keywords[5].id | https://openalex.org/keywords/retrospective-cohort-study |
| keywords[5].score | 0.5178266167640686 |
| keywords[5].display_name | Retrospective cohort study |
| keywords[6].id | https://openalex.org/keywords/cohort |
| keywords[6].score | 0.4839220643043518 |
| keywords[6].display_name | Cohort |
| keywords[7].id | https://openalex.org/keywords/lung-cancer |
| keywords[7].score | 0.46925947070121765 |
| keywords[7].display_name | Lung cancer |
| keywords[8].id | https://openalex.org/keywords/nivolumab |
| keywords[8].score | 0.4629533886909485 |
| keywords[8].display_name | Nivolumab |
| keywords[9].id | https://openalex.org/keywords/cancer |
| keywords[9].score | 0.3675593137741089 |
| keywords[9].display_name | Cancer |
| keywords[10].id | https://openalex.org/keywords/surgery |
| keywords[10].score | 0.33880293369293213 |
| keywords[10].display_name | Surgery |
| keywords[11].id | https://openalex.org/keywords/confidence-interval |
| keywords[11].score | 0.1734839379787445 |
| keywords[11].display_name | Confidence interval |
| keywords[12].id | https://openalex.org/keywords/immunotherapy |
| keywords[12].score | 0.1676752269268036 |
| keywords[12].display_name | Immunotherapy |
| language | en |
| locations[0].id | doi:10.6004/jnccn.2020.7668 |
| locations[0].is_oa | False |
| locations[0].source.id | https://openalex.org/S935620192 |
| locations[0].source.issn | 1540-1405, 1540-1413 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1540-1405 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Journal of the National Comprehensive Cancer Network |
| locations[0].source.host_organization | https://openalex.org/P4324004213 |
| locations[0].source.host_organization_name | National Comprehensive Cancer |
| locations[0].source.host_organization_lineage | https://openalex.org/P4324004213 |
| locations[0].source.host_organization_lineage_names | National Comprehensive Cancer |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of the National Comprehensive Cancer Network |
| locations[0].landing_page_url | https://doi.org/10.6004/jnccn.2020.7668 |
| locations[1].id | pmid:33878726 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Journal of the National Comprehensive Cancer Network : JNCCN |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/33878726 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:8752085 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | J Natl Compr Canc Netw |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/8752085 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5021394498 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Angel Qin |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I27837315 |
| authorships[0].affiliations[0].raw_affiliation_string | 1Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan. |
| authorships[0].institutions[0].id | https://openalex.org/I27837315 |
| authorships[0].institutions[0].ror | https://ror.org/00jmfr291 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I27837315 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | University of Michigan |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Angel Qin |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | 1Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan. |
| authorships[1].author.id | https://openalex.org/A5109508555 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Songzhu Zhao |
| authorships[1].affiliations[0].raw_affiliation_string | 2Center for Biostatistics. |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Songzhu Zhao |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | 2Center for Biostatistics. |
| authorships[2].author.id | https://openalex.org/A5006900391 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-4179-6036 |
| authorships[2].author.display_name | Abdul Miah |
| authorships[2].affiliations[0].raw_affiliation_string | 3Division of Medical Oncology, and. |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Abdul Miah |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | 3Division of Medical Oncology, and. |
| authorships[3].author.id | https://openalex.org/A5029524605 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-7248-3828 |
| authorships[3].author.display_name | Lai Wei |
| authorships[3].affiliations[0].raw_affiliation_string | 2Center for Biostatistics. |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Lai Wei |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | 2Center for Biostatistics. |
| authorships[4].author.id | https://openalex.org/A5078689933 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-7803-8920 |
| authorships[4].author.display_name | Sandipkumar Patel |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I52357470 |
| authorships[4].affiliations[0].raw_affiliation_string | 4Department of Internal Medicine, The Ohio State University, Columbus, Ohio. |
| authorships[4].institutions[0].id | https://openalex.org/I52357470 |
| authorships[4].institutions[0].ror | https://ror.org/00rs6vg23 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I52357470 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | The Ohio State University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Sandipkumar Patel |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | 4Department of Internal Medicine, The Ohio State University, Columbus, Ohio. |
| authorships[5].author.id | https://openalex.org/A5013111309 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-9821-8662 |
| authorships[5].author.display_name | Andrew Johns |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I52357470 |
| authorships[5].affiliations[0].raw_affiliation_string | 4Department of Internal Medicine, The Ohio State University, Columbus, Ohio. |
| authorships[5].institutions[0].id | https://openalex.org/I52357470 |
| authorships[5].institutions[0].ror | https://ror.org/00rs6vg23 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I52357470 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | The Ohio State University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Andrew Johns |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | 4Department of Internal Medicine, The Ohio State University, Columbus, Ohio. |
| authorships[6].author.id | https://openalex.org/A5059895822 |
| authorships[6].author.orcid | https://orcid.org/0009-0000-1517-4829 |
| authorships[6].author.display_name | Madison Grogan |
| authorships[6].affiliations[0].raw_affiliation_string | 3Division of Medical Oncology, and. |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Madison Grogan |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | 3Division of Medical Oncology, and. |
| authorships[7].author.id | https://openalex.org/A5090253314 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-3174-0928 |
| authorships[7].author.display_name | Erin M. Bertino |
| authorships[7].affiliations[0].raw_affiliation_string | 3Division of Medical Oncology, and. |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Erin M. Bertino |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | 3Division of Medical Oncology, and. |
| authorships[8].author.id | https://openalex.org/A5075792907 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-4378-9297 |
| authorships[8].author.display_name | Kai He |
| authorships[8].affiliations[0].raw_affiliation_string | 3Division of Medical Oncology, and. |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Kai He |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | 3Division of Medical Oncology, and. |
| authorships[9].author.id | https://openalex.org/A5079716545 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-7404-217X |
| authorships[9].author.display_name | Peter G. Shields |
| authorships[9].affiliations[0].raw_affiliation_string | 3Division of Medical Oncology, and. |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Peter G. Shields |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | 3Division of Medical Oncology, and. |
| authorships[10].author.id | https://openalex.org/A5066306817 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-2404-7420 |
| authorships[10].author.display_name | Gregory P. Kalemkerian |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I27837315 |
| authorships[10].affiliations[0].raw_affiliation_string | 1Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan. |
| authorships[10].institutions[0].id | https://openalex.org/I27837315 |
| authorships[10].institutions[0].ror | https://ror.org/00jmfr291 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I27837315 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | University of Michigan |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Gregory P. Kalemkerian |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | 1Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan. |
| authorships[11].author.id | https://openalex.org/A5025836672 |
| authorships[11].author.orcid | https://orcid.org/0000-0001-5240-3811 |
| authorships[11].author.display_name | Shirish M. Gadgeel |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I2803043754 |
| authorships[11].affiliations[0].raw_affiliation_string | 5Division of Hematology and Oncology, Henry Ford Cancer Center, Detroit, Michigan; |
| authorships[11].affiliations[1].institution_ids | https://openalex.org/I27837315, https://openalex.org/I2803043754 |
| authorships[11].affiliations[1].raw_affiliation_string | 1Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan;; 5Division of Hematology and Oncology, Henry Ford Cancer Center, Detroit, Michigan; |
| authorships[11].institutions[0].id | https://openalex.org/I2803043754 |
| authorships[11].institutions[0].ror | https://ror.org/0193sb042 |
| authorships[11].institutions[0].type | healthcare |
| authorships[11].institutions[0].lineage | https://openalex.org/I154057602, https://openalex.org/I2803043754 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | Henry Ford Hospital |
| authorships[11].institutions[1].id | https://openalex.org/I27837315 |
| authorships[11].institutions[1].ror | https://ror.org/00jmfr291 |
| authorships[11].institutions[1].type | education |
| authorships[11].institutions[1].lineage | https://openalex.org/I27837315 |
| authorships[11].institutions[1].country_code | US |
| authorships[11].institutions[1].display_name | University of Michigan |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Shirish M. Gadgeel |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | 1Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan;; 5Division of Hematology and Oncology, Henry Ford Cancer Center, Detroit, Michigan;, 5Division of Hematology and Oncology, Henry Ford Cancer Center, Detroit, Michigan; |
| authorships[12].author.id | https://openalex.org/A5087704838 |
| authorships[12].author.orcid | https://orcid.org/0000-0003-3641-5630 |
| authorships[12].author.display_name | Nithya Ramnath |
| authorships[12].countries | US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I27837315 |
| authorships[12].affiliations[0].raw_affiliation_string | 1Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan. |
| authorships[12].institutions[0].id | https://openalex.org/I27837315 |
| authorships[12].institutions[0].ror | https://ror.org/00jmfr291 |
| authorships[12].institutions[0].type | education |
| authorships[12].institutions[0].lineage | https://openalex.org/I27837315 |
| authorships[12].institutions[0].country_code | US |
| authorships[12].institutions[0].display_name | University of Michigan |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Nithya Ramnath |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | 1Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan. |
| authorships[13].author.id | https://openalex.org/A5028299369 |
| authorships[13].author.orcid | https://orcid.org/0000-0003-4189-3805 |
| authorships[13].author.display_name | Bryan J. Schneider |
| authorships[13].countries | US |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I27837315 |
| authorships[13].affiliations[0].raw_affiliation_string | 1Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan. |
| authorships[13].institutions[0].id | https://openalex.org/I27837315 |
| authorships[13].institutions[0].ror | https://ror.org/00jmfr291 |
| authorships[13].institutions[0].type | education |
| authorships[13].institutions[0].lineage | https://openalex.org/I27837315 |
| authorships[13].institutions[0].country_code | US |
| authorships[13].institutions[0].display_name | University of Michigan |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Bryan J. Schneider |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | 1Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan. |
| authorships[14].author.id | https://openalex.org/A5056827435 |
| authorships[14].author.orcid | https://orcid.org/0009-0001-3631-711X |
| authorships[14].author.display_name | Khaled A. Hassan |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I1316902750, https://openalex.org/I27837315 |
| authorships[14].affiliations[0].raw_affiliation_string | 1Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan;; 6Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio; and |
| authorships[14].affiliations[1].institution_ids | https://openalex.org/I1316902750 |
| authorships[14].affiliations[1].raw_affiliation_string | 6Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio; and |
| authorships[14].institutions[0].id | https://openalex.org/I1316902750 |
| authorships[14].institutions[0].ror | https://ror.org/03xjacd83 |
| authorships[14].institutions[0].type | healthcare |
| authorships[14].institutions[0].lineage | https://openalex.org/I1316902750 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | Cleveland Clinic |
| authorships[14].institutions[1].id | https://openalex.org/I27837315 |
| authorships[14].institutions[1].ror | https://ror.org/00jmfr291 |
| authorships[14].institutions[1].type | education |
| authorships[14].institutions[1].lineage | https://openalex.org/I27837315 |
| authorships[14].institutions[1].country_code | US |
| authorships[14].institutions[1].display_name | University of Michigan |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Khaled A. Hassan |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | 1Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan;; 6Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio; and, 6Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio; and |
| authorships[15].author.id | https://openalex.org/A5069705336 |
| authorships[15].author.orcid | https://orcid.org/0000-0003-1116-3422 |
| authorships[15].author.display_name | Nicholas J. Szerlip |
| authorships[15].affiliations[0].raw_affiliation_string | 7Department of Neurosurgery. |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Nicholas Szerlip |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | 7Department of Neurosurgery. |
| authorships[16].author.id | https://openalex.org/A5036961774 |
| authorships[16].author.orcid | https://orcid.org/0000-0002-6349-2431 |
| authorships[16].author.display_name | Zoey Chopra |
| authorships[16].countries | US |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210128700 |
| authorships[16].affiliations[0].raw_affiliation_string | 8Department of Medical Education, and. |
| authorships[16].institutions[0].id | https://openalex.org/I4210128700 |
| authorships[16].institutions[0].ror | https://ror.org/030sy9j53 |
| authorships[16].institutions[0].type | healthcare |
| authorships[16].institutions[0].lineage | https://openalex.org/I4210128700 |
| authorships[16].institutions[0].country_code | US |
| authorships[16].institutions[0].display_name | St. Luke's Hospital |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Zoey Chopra |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | 8Department of Medical Education, and. |
| authorships[17].author.id | https://openalex.org/A5006218162 |
| authorships[17].author.orcid | |
| authorships[17].author.display_name | Sara N. Journey |
| authorships[17].countries | US |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I4210128700 |
| authorships[17].affiliations[0].raw_affiliation_string | 8Department of Medical Education, and. |
| authorships[17].institutions[0].id | https://openalex.org/I4210128700 |
| authorships[17].institutions[0].ror | https://ror.org/030sy9j53 |
| authorships[17].institutions[0].type | healthcare |
| authorships[17].institutions[0].lineage | https://openalex.org/I4210128700 |
| authorships[17].institutions[0].country_code | US |
| authorships[17].institutions[0].display_name | St. Luke's Hospital |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Sara Journey |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | 8Department of Medical Education, and. |
| authorships[18].author.id | https://openalex.org/A5054960097 |
| authorships[18].author.orcid | https://orcid.org/0000-0002-5172-5779 |
| authorships[18].author.display_name | Jessica Waninger |
| authorships[18].countries | US |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I4210128700 |
| authorships[18].affiliations[0].raw_affiliation_string | 8Department of Medical Education, and. |
| authorships[18].institutions[0].id | https://openalex.org/I4210128700 |
| authorships[18].institutions[0].ror | https://ror.org/030sy9j53 |
| authorships[18].institutions[0].type | healthcare |
| authorships[18].institutions[0].lineage | https://openalex.org/I4210128700 |
| authorships[18].institutions[0].country_code | US |
| authorships[18].institutions[0].display_name | St. Luke's Hospital |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Jessica Waninger |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | 8Department of Medical Education, and. |
| authorships[19].author.id | https://openalex.org/A5031691358 |
| authorships[19].author.orcid | https://orcid.org/0000-0003-2314-6435 |
| authorships[19].author.display_name | Daniel Spakowicz |
| authorships[19].affiliations[0].raw_affiliation_string | 2Center for Biostatistics. |
| authorships[19].affiliations[1].raw_affiliation_string | 3Division of Medical Oncology, and |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Daniel Spakowicz |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | 2Center for Biostatistics., 3Division of Medical Oncology, and |
| authorships[20].author.id | https://openalex.org/A5059652753 |
| authorships[20].author.orcid | https://orcid.org/0000-0003-3002-1921 |
| authorships[20].author.display_name | David P. Carbone |
| authorships[20].affiliations[0].raw_affiliation_string | 3Division of Medical Oncology, and. |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | David P. Carbone |
| authorships[20].is_corresponding | False |
| authorships[20].raw_affiliation_strings | 3Division of Medical Oncology, and. |
| authorships[21].author.id | https://openalex.org/A5006468163 |
| authorships[21].author.orcid | https://orcid.org/0000-0002-2607-5639 |
| authorships[21].author.display_name | Carolyn J. Presley |
| authorships[21].affiliations[0].raw_affiliation_string | 3Division of Medical Oncology, and. |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Carolyn J. Presley |
| authorships[21].is_corresponding | False |
| authorships[21].raw_affiliation_strings | 3Division of Medical Oncology, and. |
| authorships[22].author.id | https://openalex.org/A5004712121 |
| authorships[22].author.orcid | https://orcid.org/0000-0001-9877-8512 |
| authorships[22].author.display_name | Gregory A. Otterson |
| authorships[22].affiliations[0].raw_affiliation_string | 3Division of Medical Oncology, and. |
| authorships[22].author_position | middle |
| authorships[22].raw_author_name | Gregory A. Otterson |
| authorships[22].is_corresponding | False |
| authorships[22].raw_affiliation_strings | 3Division of Medical Oncology, and. |
| authorships[23].author.id | https://openalex.org/A5032271799 |
| authorships[23].author.orcid | https://orcid.org/0000-0003-4951-7118 |
| authorships[23].author.display_name | Michael D. Green |
| authorships[23].countries | US |
| authorships[23].affiliations[0].institution_ids | https://openalex.org/I27837315 |
| authorships[23].affiliations[0].raw_affiliation_string | 9Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. |
| authorships[23].institutions[0].id | https://openalex.org/I27837315 |
| authorships[23].institutions[0].ror | https://ror.org/00jmfr291 |
| authorships[23].institutions[0].type | education |
| authorships[23].institutions[0].lineage | https://openalex.org/I27837315 |
| authorships[23].institutions[0].country_code | US |
| authorships[23].institutions[0].display_name | University of Michigan |
| authorships[23].author_position | middle |
| authorships[23].raw_author_name | Michael D. Green |
| authorships[23].is_corresponding | False |
| authorships[23].raw_affiliation_strings | 9Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. |
| authorships[24].author.id | https://openalex.org/A5091280788 |
| authorships[24].author.orcid | https://orcid.org/0000-0002-6598-4886 |
| authorships[24].author.display_name | Dwight H. Owen |
| authorships[24].affiliations[0].raw_affiliation_string | 3Division of Medical Oncology, and. |
| authorships[24].author_position | last |
| authorships[24].raw_author_name | Dwight H. Owen |
| authorships[24].is_corresponding | False |
| authorships[24].raw_affiliation_strings | 3Division of Medical Oncology, and. |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.ncbi.nlm.nih.gov/pmc/articles/8752085 |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T12379 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998000264167786 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Cancer Diagnosis and Treatment |
| related_works | https://openalex.org/W4388586239, https://openalex.org/W2898986397, https://openalex.org/W3021851930, https://openalex.org/W2981652925, https://openalex.org/W2800160190, https://openalex.org/W2890849069, https://openalex.org/W3004135494, https://openalex.org/W4221108986, https://openalex.org/W2994686985, https://openalex.org/W4281722959 |
| cited_by_count | 48 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 9 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 14 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 13 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 10 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 1 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 1 |
| locations_count | 3 |
| best_oa_location.id | pmh:oai:pubmedcentral.nih.gov:8752085 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764455111 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | PubMed Central |
| best_oa_location.source.host_organization | https://openalex.org/I1299303238 |
| best_oa_location.source.host_organization_name | National Institutes of Health |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I1299303238 |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | submittedVersion |
| best_oa_location.raw_type | Text |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | J Natl Compr Canc Netw |
| best_oa_location.landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/8752085 |
| primary_location.id | doi:10.6004/jnccn.2020.7668 |
| primary_location.is_oa | False |
| primary_location.source.id | https://openalex.org/S935620192 |
| primary_location.source.issn | 1540-1405, 1540-1413 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1540-1405 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Journal of the National Comprehensive Cancer Network |
| primary_location.source.host_organization | https://openalex.org/P4324004213 |
| primary_location.source.host_organization_name | National Comprehensive Cancer |
| primary_location.source.host_organization_lineage | https://openalex.org/P4324004213 |
| primary_location.source.host_organization_lineage_names | National Comprehensive Cancer |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of the National Comprehensive Cancer Network |
| primary_location.landing_page_url | https://doi.org/10.6004/jnccn.2020.7668 |
| publication_date | 2021-08-01 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W2992931937, https://openalex.org/W3029424640, https://openalex.org/W1996589664, https://openalex.org/W2589779611, https://openalex.org/W2149775776, https://openalex.org/W2736693360, https://openalex.org/W2940307933, https://openalex.org/W2087769940, https://openalex.org/W2137083298, https://openalex.org/W2614029538, https://openalex.org/W3003716965, https://openalex.org/W2038982031, https://openalex.org/W2990769829, https://openalex.org/W2889444510, https://openalex.org/W2982970399, https://openalex.org/W2796582438, https://openalex.org/W2084460361, https://openalex.org/W2912571746, https://openalex.org/W2809385373, https://openalex.org/W2224941815, https://openalex.org/W2922201966, https://openalex.org/W2950235098, https://openalex.org/W2048420147, https://openalex.org/W2986872802, https://openalex.org/W2991387714, https://openalex.org/W2093274439, https://openalex.org/W2588675203 |
| referenced_works_count | 27 |
| abstract_inverted_index.2 | 97 |
| abstract_inverted_index.A | 122 |
| abstract_inverted_index.P | 246 |
| abstract_inverted_index.a | 8, 78, 86, 119, 151, 223, 257, 272, 298 |
| abstract_inverted_index.10 | 193 |
| abstract_inverted_index.43 | 209 |
| abstract_inverted_index.63 | 167 |
| abstract_inverted_index.In | 198 |
| abstract_inverted_index.OS | 133, 191, 255 |
| abstract_inverted_index.We | 84, 149 |
| abstract_inverted_index.at | 96, 140, 267 |
| abstract_inverted_index.in | 13, 30, 48, 70, 77, 173, 300 |
| abstract_inverted_index.of | 11, 44, 68, 89, 137, 153, 226, 235, 249, 260, 264, 289 |
| abstract_inverted_index.on | 25, 41, 57 |
| abstract_inverted_index.or | 177, 214, 256, 297 |
| abstract_inverted_index.to | 128 |
| abstract_inverted_index.we | 52 |
| abstract_inverted_index.124 | 201 |
| abstract_inverted_index.330 | 154 |
| abstract_inverted_index.95% | 243 |
| abstract_inverted_index.CI, | 196, 244 |
| abstract_inverted_index.Cox | 123 |
| abstract_inverted_index.ICI | 141, 187, 216, 281 |
| abstract_inverted_index.Use | 248, 288 |
| abstract_inverted_index.age | 165 |
| abstract_inverted_index.and | 3, 28, 40, 64, 66, 82, 113, 134, 181, 208, 237 |
| abstract_inverted_index.are | 7, 23 |
| abstract_inverted_index.for | 61, 144, 160, 230, 275, 284 |
| abstract_inverted_index.had | 157, 204, 222 |
| abstract_inverted_index.not | 252, 292 |
| abstract_inverted_index.our | 199 |
| abstract_inverted_index.the | 42, 54, 130, 135, 174, 184 |
| abstract_inverted_index.was | 108, 126, 166, 183, 192, 251, 269, 291 |
| abstract_inverted_index.who | 156 |
| abstract_inverted_index.(95% | 195 |
| abstract_inverted_index.(OS) | 107 |
| abstract_inverted_index.2014 | 102 |
| abstract_inverted_index.BMAs | 69, 250, 290 |
| abstract_inverted_index.Bone | 1 |
| abstract_inverted_index.Data | 22 |
| abstract_inverted_index.Here | 51 |
| abstract_inverted_index.ICIs | 76, 95, 159 |
| abstract_inverted_index.SREs | 29, 212, 296 |
| abstract_inverted_index.bone | 26, 62, 116, 138, 206, 220, 265 |
| abstract_inverted_index.care | 99 |
| abstract_inverted_index.cell | 18 |
| abstract_inverted_index.from | 101 |
| abstract_inverted_index.line | 176, 234 |
| abstract_inverted_index.lung | 19 |
| abstract_inverted_index.most | 169, 185 |
| abstract_inverted_index.risk | 59, 259 |
| abstract_inverted_index.this | 49 |
| abstract_inverted_index.used | 127 |
| abstract_inverted_index.were | 171 |
| abstract_inverted_index.with | 15, 32, 72, 75, 91, 94, 112, 219, 254, 271, 277, 280, 294 |
| abstract_inverted_index.(13%) | 210 |
| abstract_inverted_index.(38%) | 203 |
| abstract_inverted_index.1.57; | 242 |
| abstract_inverted_index.2017. | 104 |
| abstract_inverted_index.64%). | 189 |
| abstract_inverted_index.78%), | 180 |
| abstract_inverted_index.SREs, | 65 |
| abstract_inverted_index.SREs. | 261 |
| abstract_inverted_index.after | 215, 228, 282 |
| abstract_inverted_index.cause | 10 |
| abstract_inverted_index.death | 227 |
| abstract_inverted_index.model | 125 |
| abstract_inverted_index.other | 145 |
| abstract_inverted_index.study | 88 |
| abstract_inverted_index.test. | 121 |
| abstract_inverted_index.using | 35, 118 |
| abstract_inverted_index.worse | 273 |
| abstract_inverted_index.(BMAs) | 47 |
| abstract_inverted_index.(SREs) | 6 |
| abstract_inverted_index.Median | 163, 190 |
| abstract_inverted_index.agents | 46 |
| abstract_inverted_index.beyond | 178 |
| abstract_inverted_index.burden | 239 |
| abstract_inverted_index.cancer | 20 |
| abstract_inverted_index.cohort | 152 |
| abstract_inverted_index.common | 186 |
| abstract_inverted_index.during | 213 |
| abstract_inverted_index.events | 5 |
| abstract_inverted_index.hazard | 225 |
| abstract_inverted_index.higher | 224 |
| abstract_inverted_index.immune | 36 |
| abstract_inverted_index.impact | 56, 67 |
| abstract_inverted_index.mNSCLC | 33, 73, 92, 278 |
| abstract_inverted_index.months | 194 |
| abstract_inverted_index.ratio, | 241 |
| abstract_inverted_index.report | 53 |
| abstract_inverted_index.second | 175 |
| abstract_inverted_index.years, | 168 |
| abstract_inverted_index.(ICIs), | 39 |
| abstract_inverted_index.(hazard | 240 |
| abstract_inverted_index.(n=211; | 188 |
| abstract_inverted_index.(n=259; | 179 |
| abstract_inverted_index.=.001). | 247 |
| abstract_inverted_index.Overall | 105 |
| abstract_inverted_index.between | 110, 132 |
| abstract_inverted_index.centers | 100 |
| abstract_inverted_index.cohort, | 200 |
| abstract_inverted_index.cohort. | 80 |
| abstract_inverted_index.disease | 238 |
| abstract_inverted_index.factors | 60 |
| abstract_inverted_index.limited | 24 |
| abstract_inverted_index.patient | 164 |
| abstract_inverted_index.reduced | 295 |
| abstract_inverted_index.status, | 232 |
| abstract_inverted_index.through | 103 |
| abstract_inverted_index.treated | 34, 74, 93, 172, 279 |
| abstract_inverted_index.without | 114 |
| abstract_inverted_index.Methods: | 83 |
| abstract_inverted_index.Patients | 81, 218 |
| abstract_inverted_index.Presence | 263 |
| abstract_inverted_index.Results: | 148 |
| abstract_inverted_index.baseline | 115, 205, 268 |
| abstract_inverted_index.clinical | 286 |
| abstract_inverted_index.compared | 109 |
| abstract_inverted_index.disease. | 162 |
| abstract_inverted_index.efficacy | 43 |
| abstract_inverted_index.evaluate | 129 |
| abstract_inverted_index.factors. | 147 |
| abstract_inverted_index.frequent | 9 |
| abstract_inverted_index.log-rank | 120 |
| abstract_inverted_index.multiple | 285 |
| abstract_inverted_index.patients | 14, 31, 71, 90, 111, 155, 170, 202, 276 |
| abstract_inverted_index.presence | 136 |
| abstract_inverted_index.received | 158 |
| abstract_inverted_index.setting. | 50 |
| abstract_inverted_index.survival | 106 |
| abstract_inverted_index.tertiary | 98 |
| abstract_inverted_index.therapy, | 236 |
| abstract_inverted_index.(mNSCLC). | 21 |
| abstract_inverted_index.conducted | 85 |
| abstract_inverted_index.decreased | 258 |
| abstract_inverted_index.developed | 211 |
| abstract_inverted_index.morbidity | 12 |
| abstract_inverted_index.nivolumab | 182 |
| abstract_inverted_index.prognosis | 274 |
| abstract_inverted_index.survival, | 58 |
| abstract_inverted_index.survival. | 301 |
| abstract_inverted_index.associated | 253, 270, 293 |
| abstract_inverted_index.checkpoint | 37 |
| abstract_inverted_index.difference | 299 |
| abstract_inverted_index.histology, | 233 |
| abstract_inverted_index.identified | 150 |
| abstract_inverted_index.incidence, | 55 |
| abstract_inverted_index.inhibitors | 38 |
| abstract_inverted_index.metastases | 2, 27, 63, 117, 139, 221, 266 |
| abstract_inverted_index.metastatic | 16, 161 |
| abstract_inverted_index.regression | 124 |
| abstract_inverted_index.treatment. | 217 |
| abstract_inverted_index.Background: | 0 |
| abstract_inverted_index.association | 131 |
| abstract_inverted_index.confounding | 146 |
| abstract_inverted_index.controlling | 143, 229, 283 |
| abstract_inverted_index.initiation, | 142 |
| abstract_inverted_index.metastases, | 207 |
| abstract_inverted_index.non–small | 17 |
| abstract_inverted_index.performance | 231 |
| abstract_inverted_index.1.19–2.08; | 245 |
| abstract_inverted_index.8.4–12.0). | 197 |
| abstract_inverted_index.Conclusions: | 262 |
| abstract_inverted_index.retrospective | 87 |
| abstract_inverted_index.bone-modifying | 45 |
| abstract_inverted_index.characteristics. | 287 |
| abstract_inverted_index.skeletal-related | 4 |
| abstract_inverted_index.multi-institutional | 79 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 89 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 25 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8399999737739563 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.94900076 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |